Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC
EBioMedicine 2018;36, 1828, doi: Zhu, Y
Regular follow-up appointments allow your provider to monitor treatment response, adjust dosages as needed, and address any adverse effects
For most patients, this change is mild and not harmful
But we dont recommend that you do so
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies